Drugs / ATTO-3712
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07205081 | Oct 2025 → Oct 2026 expected | atopic eczema | Attovia Therapeutics Inc | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATTO-3712 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07205081 ↗ |
| Route | Intravenous | “ATTO-3712 Dose level cohorts receiving a single dose IV” NCT07205081 ↗ |